Amicogen Extends Investment Period for Endolysin cGMP Facility by One Year, Limited Shareholder Value Impact from Minor Amendment

Amicogen submitted a correction disclosure on June 30, 2026, extending the investment end date for its new facility investment from June 30, 2026 to June 30, 2027, a one-year extension.
This amendment solely changes the end date due to an extension of the investment period for the endolysin cGMP manufacturing facility, while the investment amount of 11.5 billion KRW and all other terms remain unchanged.
The disclosure is a routine administrative adjustment with no new capital raising or dilution effects, thus having a very limited impact on existing shareholder value.
[AI Summary]The extension of the end date for Amicogen's endolysin cGMP facility investment is an administrative extension without changes in investment size or terms, resulting in no new funding or equity dilution, and thus a neutral impact on shareholder value. As there is no substantive change from the original investment plan, it does not constitute a significant variable for investment decisions.